Gonadorelin

approved

Also known as: GnRH, LHRH, Factrel

**Mechanism of Action** Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on anterior pituitary gonadotroph cells, stimulating the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This action is dose- and frequency-dependent: pulsatile administration mimics physiological GnRH release, promoting gonadal steroidogenesis and gametogenesis, while continuous exposure leads to receptor desensitization and suppression of gonadotropin secretion. **Key Research Findings** Clinical studies confirm that intravenous or subcutaneous gonadorelin reliably induces LH and FSH peaks within 30–60 minutes, with LH responses used diagnostically to assess pituitary-gonadal axis integrity (e.g., in hypogonadotropic hypogonadism). Research demonstrates its efficacy in inducing ovulation in anovulatory women with hypothalamic amenorrhea when administered via pulsatile pump, achieving pregnancy rates comparable to endogenous cycles. In males, it supports testosterone production in select cases of secondary hypogonadism. Long-term continuous use is avoided due to paradoxical suppression of gonadal function. **Clinical Relevance** Gonadorelin is FDA-approved for diagnostic testing of pituitary function and for therapeutic induction of ovulation in women with hypothalamic amenorrhea. Its short half-life (~4 minutes) necessitates pulsatile delivery for therapeutic use. Off-label applications include controlled ovarian stimulation in assisted reproduction and evaluation of delayed puberty. Adverse effects are minimal but may include local injection site reactions, nausea, or transient headache. For research purposes only — not medical advice.

Key data

Category
Hormonal & Endocrine
Molecular weight
1182.3 g/mol
Molecular formula
C55H75N17O13
CAS number
33515-09-2
Administration
subcutaneous, intravenous
Research status
approved
References
294
Tags
gnrh, approved, reproductive

Research & studies

Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin
Journal of pharmaceutical and biomedical analysis · 2023 · PubMed
Endometriosis: the effects of dienogest
BMJ clinical evidence · 2015 · PubMed
Menorrhagia
BMJ clinical evidence · 2012 · PubMed

Menorrhagia causes anemia in two-thirds of women with objective blood loss ≥80 mL per cycle.; Fibroids are found in 10% of women with menorrhagia overall and 40% with severe menorrhagia.; Half of women undergoing hysterectomy for menorrhagia have a normal uterus.; Prostaglandin disorders may be linked to idiopathic menorrhagia and heavy bleeding from fibroids, adenomyosis, or IUDs.

Breast pain
BMJ clinical evidence · 2011 · PubMed
Fibroids (uterine myomatosis, leiomyomas)
BMJ clinical evidence · 2011 · PubMed
Breast cancer (metastatic)
BMJ clinical evidence · 2010 · PubMed
Endometriosis
BMJ clinical evidence · 2010 · PubMed

Ectopic endometrial tissue prevalence ranges from 1.5% to 6.2% in women of reproductive age, up to 60% in those with dysmenorrhea, and up to 30% in women with subfertility.; Symptoms of endometriosis may not correlate with laparoscopic findings.; The review evaluated interventions including combined oral contraceptives, danazol, gonadorelin analogues, aromatase inhibitors, and surgical options like laparoscopic cystectomy and removal of deposits.; GRADE evaluation was performed to assess the quality of evidence for each intervention.

Menorrhagia
BMJ clinical evidence · 2008 · PubMed

Frequently asked questions

What is Gonadorelin?

**Mechanism of Action** Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on anterior pituitary gonadotroph cells, stimulating the synthesis and pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This actio

How does Gonadorelin work?

Synthetic GnRH decapeptide that stimulates pituitary LH and FSH release; used diagnostically and to support gonadal function.

What is the research status of Gonadorelin?

Gonadorelin is currently classified as approved, with 294 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Gonadorelin?

Gonadorelin has a molecular weight of approximately 1182.3 g/mol (formula C55H75N17O13).

Related peptides

Build on Gonadorelin data programmatically

Structured peptide data, semantic search, and AI summaries via one API.

Get a free API key